Erratum for Ajani et al., J Clin Oncol 25 (22) 3205-3209.

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?

ERRATUM

The Title should not have included the word "Cancer," and should have read:

"Clinical Benefit With Docetaxel Plus Fluorouracil and Cisplatin Compared With Cisplatin and Fluorouracil in a Phase III Trial of Advanced Gastric or Gastroesophageal Adenocarcinoma: The V-325 Study Group"

In Table 2, the last footnote was given as:

"Defined as the first opioid intake for grade > 3 cancer pain or death if death was the reason for treatment discontinuation; percent of assessable patients with an event is shown in parenthesis."

While it should have read:

"Defined as the first opioid intake for grade > 3 cancer pain or death if death was the reason for treatment discontinuation."

In the Author Contributions section, all authors should have been acknowledged for "Collection and assembly of data."

The online version has been corrected in departure from the print.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This Article Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Search for Related Content Social Bookmarking                            What's this?